טוען...
Generalization of the time-to-event continual reassessment method to bivariate outcomes
This article considers the problem of designing Phase I-II clinical trials with delayed toxicity and efficacy outcomes. The proposed design is motivated by a Phase I-II study evaluating all-trans retinoic acid (ATRA) in combination with a fixed dose of daratumumab in the treatment of relapsed or ref...
שמור ב:
| הוצא לאור ב: | J Biopharm Stat |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2019
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6823630/ https://ncbi.nlm.nih.gov/pubmed/31264936 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10543406.2019.1634087 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|